enVVeno Medical Corporation

NasdaqCM:NVNO Stock Report

Market Cap: US$54.5m

enVVeno Medical Future Growth

Future criteria checks 2/6

enVVeno Medical is forecast to grow earnings and revenue by 32.9% and 96.7% per annum respectively while EPS is expected to grow by 41.7% per annum.

Key information

32.9%

Earnings growth rate

41.7%

EPS growth rate

Medical Equipment earnings growth12.5%
Revenue growth rate96.7%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Aug 2024

Recent future growth updates

Recent updates

enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans

Nov 27
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Aug 14
Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Apr 22
Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Dec 21
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

enVVeno Medical: Unique Exposure To Venous Treatment Domain

Sep 23

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Aug 23
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

Aug 03

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

May 10
We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Jan 25
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 08

Hancock Jaffe Laboratories finance chief sheds interim tag

Dec 31

Hancock Jaffe approves 1:25 reverse stock split

Nov 27

Earnings and Revenue Growth Forecasts

NasdaqCM:NVNO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027491N/AN/A1
12/31/202622-19N/A-71
12/31/20254-25N/A71
12/31/2024N/A-22N/A-241
9/30/2024N/A-21-17-17N/A
6/30/2024N/A-21-17-17N/A
3/31/2024N/A-22-17-17N/A
12/31/2023N/A-24-19-19N/A
9/30/2023N/A-24-18-18N/A
6/30/2023N/A-25-18-18N/A
3/31/2023N/A-26-17-17N/A
12/31/2022N/A-25-16-16N/A
9/30/2022N/A-27-15-15N/A
6/30/2022N/A-24-13-13N/A
3/31/2022N/A-19-12-11N/A
12/31/2021N/A-17-12-12N/A
9/30/2021N/A-12-12-11N/A
6/30/2021N/A-12-12-12N/A
3/31/2021N/A-11-11-10N/A
12/31/2020N/A-10-8-8N/A
9/30/2020N/A-7-7-7N/A
6/30/2020N/A-7-6-5N/A
3/31/2020N/A-7-6-6N/A
12/31/20190-8-6-6N/A
9/30/20190-7-6-6N/A
6/30/20190-7-6-6N/A
3/31/20190-13-6-6N/A
12/31/20180-16-6-6N/A
9/30/20180-18-6-6N/A
6/30/20180-19N/A-6N/A
3/31/20180-12N/A-5N/A
12/31/20170-8N/A-4N/A
9/30/20171-7N/A-4N/A
6/30/20171-5N/A-3N/A
3/31/20171-6N/A-3N/A
12/31/20161-6N/A-3N/A
9/30/20160-5N/A-4N/A
12/31/2015N/A-1N/A-2N/A
12/31/20140-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVNO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NVNO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NVNO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NVNO's revenue (96.7% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: NVNO's revenue (96.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NVNO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 22:53
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

enVVeno Medical Corporation is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey CohenLadenburg Thalmann & Company